Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Corporate Update (June 2026)
24 slides from Legend Biotech's corporate update, Jun 15, 2026
Slide 1: EHA 2026 Recap
EHA 2026 Recap June 2026 © 2026 Legend Biotech. All rights reserved.
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigati
Slide 3: Agenda
3 Agenda In Vivo Platform Overview 1 Recap of LB2501 Data from EHA 2026 2 Next Steps 3 Q&A 4
Slide 4: In Vivo Platform Overview
IN VIVO PLATFORM OVERVIEW
Slide 5: In Vivo Delivery: A next generation approach to off-the-shelf CAR-T
5 In Vivo Delivery A next generation approach to off - the - shelf CAR - T 1 • Better CAR - T cell fitness • Off - the - shelf therapy • No lymphodepletion necessary • Scalable manufacturing Ex vivo CAR - T In vivo CAR - T non - targeted virus engineered cell is drug product engineered virus is drug
Slide 6: In Vivo TaVec (T-Cell Activation Vector) Design and Mechanism of Action
6 Leveraging Stand - Alone Cell Therapy Leadership In Vivo TaVec (T - Cell Activation Vector) Design and Mechanism of Action TARGET • Oncology and autoimmune indications Mechanism of Action/Scientific Rationale • Cocal glycoprotein in TaVec platform • Provide T cell specificity, activation and safet
Slide 7: Recap of LB2501 Data from EHA 2026
RECAP OF LB2501 DATA FROM EHA 2026
Slide 8: LB2501: Engineered LVV for In Vivo CD19/CD20 CAR-T Generation
8 LB2501: Engineered LVV for In Vivo CD19/CD20 CAR - T Generation • A third - generation, replication - incompetent lentiviral vector (LVV) with CD3 binder and T - cell targeting design on surface • Proprietary CD19/CD20 dual - target CAR design to broaden antigen coverage • LB2501 generates CAR -
Slide 9: Study Design
9 *Disease that did not respond to, or progressed within 12 months after completion of first - line therapy. DL: Dose Level; 1. ECOG PS Eastern Cooperative Oncology Group Performance Status ; 2. LBCL: large B - cell lymphoma; 3. iNHL : indolent lymphoma; 4. MCL: mantle cell lymphoma; 5. CLL: chronic
Slide 10: Demographics and Baseline Characteristics
10 *Both TCE therapies are CD20 × CD3. DL, dose level; 1. DLBCL, diffuse large B - Cell lymphoma; 2. FL, follicular lymphoma; 3. MCL, mantle cell lymphoma; PMBL, primary mediastinal large B - cell lymphoma; 4. SPD, sum of the product of the diameters. Demographics and Baseline Characteristics Total
Slide 11: High Objective Response Rate and Complete Response in DL2
11 • The median follow - up for DL2 was 2.3 months (range, 2.0 to 4.5). • At the data cutoff date, all responses were ongoing • In DL2 across DLBCL, MCL, and FL: • (6/6) ORR • (5/6) CR High Objective Response Rate and Complete Response in DL2 Duration of Responses in Patients (DL2) Total (N=12) DL2
Slide 12: Large Target Lesion Reductions from Baseline Across DL2
12 Large Target Lesion Reductions from Baseline Across DL2 The Lugano 2014 criteria were used to assess the response at each prespecified time point in patients with NHL Percent C hange from B aseline in SPD for B est R esponse (DL2) -100 -80 -60 -40 -20 0 20 40 Change in target lesions from baselin
Slide 13: LB2501: Pharmacokinetics
13 LB2501: Pharmacokinetics Total (N=12) DL2 (N=6) DL1 (N=6) 11 6 5 N Patients with CAR - T expansion 87,899.0 ( 51, 137,457 ) 109,117.5 ( 32,497, 137,457 ) 1,068.0 (51, 113,350) Median (Min, Max) C max 1 (copies/ug gDNA) 17.0 ( 13, 30 ) 15.0 ( 13, 18 ) 17.0 ( 14, 30 ) Median (Min, Max) T max 2 (day
Slide 14: Confirmed Expansion and Persistent PK
14 Confirmed Expansion and Persistent PK • Viral copy number in peripheral blood peaked immediately after infusion and decreased to undetectable concentrations within 24 hours • In vivo CAR - T expansion was detected by qPCR 1 in 5/6 patients (83%) at DL1 and all patients (6/6, 100%) at DL2 in a dos
Slide 15: Lentiviral integration analysis demonstrated a safe transgene profile
15 Lentiviral integration analysis demonstrated a safe transgene profile • Vector integrations were highly polyclonal and diverse with no indication of dominant clonal expansion • Integration patterns were concordant with established public HIV and LVV datasets 1,2 at both chromosomal and genomic fu
Slide 16: Safety Summary
16 DL, dose level; DLBCL, diffuse large B - Cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; MCL, ma ntle cell lymphoma; PMBL, primary mediastinal large B - cell lymphoma; SPD, sum of the product of the diameters. TEAE: Treatment - emergent adverse event; DTL, dose -
Slide 17: LB2501 LVV Infusion-Related TEAEs
17 LB2501 LVV Infusion - Related TEAEs (≥ 30%) • IRR occurred in 50% (DL1) and 100% (DL2) of patients • All Grades 1 – 2 and manageable, with a median onset of 1.4 hours after infusion and a median recovery time of 18.6 hours • No steroid prophylaxis. No IRR required tocilizumab or glucocorticoids f
Slide 18: LB2501 Generated CAR-T Related TEAEs
18 LB2501 Generated CAR - T Related TEAEs (≥30%) • CRS occurred in 33.3% (DL1) and 100% (DL2) of patients. • All Grades 1 – 2 and manageable, with a median onset at Day 11 and a median duration of 4.5 days. • Tocilizumab given to 4 patients (DL1: 1, DL2: 3); no glucocorticoids for CRS • Grade ≥3 cyt
Slide 19: Conclusions
19 Conclusions • In this First - In - Human Phase 1 study in R/R B - NHL, LB2501 showed a favorable safety profile and promising efficacy results: • LB2501 was well tolerated: no DLT, no SAE, no ICANS, and no deaths • IRR and CRS were all Grade 1 – 2, no glucocorticoid treatment • At DL2, 100% ORR a
Slide 20: Next Steps
NEXT STEPS
Slide 21: In Vivo Therapies Pipeline and Clinical Development Goals
Leveraging Stand - Alone Cell Therapy Leadership In Vivo State - of - the - art R&D facility in Philadelphia, Pennsylvania 21 Current Status Phase I Pre - Clinical Indication Target Program In Vivo Therapies Enrolling Relapsed/Refractory B - cell Non - Hodgkin Lymphoma (2) CD19 x CD20 LB2501 Enrolli
Slide 22: 22
22
Slide 23: Thank You
Slide 24: Appendix
APPENDIX